Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

If you liked this article you might like

Stock Observations; Reviewing Equities: Doug Kass' Views

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Teva's New CEO Brings This Secret Weapon

Will Allergan's Deal With Tribe Hold Up?

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)